Structure and function of the Hepatitis C Virus glycoproteins E1 and E2.

丙型肝炎病毒糖蛋白 E1 和 E2 的结构和功能。

• 批准号: nhmrc : 433913
• 负责人: A/Pr Heidi Drummer
• 金额: $ 35.6万
• 依托单位: Macfarlane Burnet Institute for Medical Research and Public Health
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/structure-function-hepatitis-e1-e2/76377
• 关键词: Structure; function; Hepatitis; Virus; glycoproteins

Hepatitis C virus (HCV) infects approximately 3 % of the global human population with 150,000-200,000 HCV-infected individuals currently living in Australia. Chronic HCV infection is associated with recurrent, progressively worsening liver disease, liver cirrhosis and hepatocellular carcinoma. The current therapy (interferon-ribavirin) is effective in only 40 % of patients and is often associated with severe side-effects. The mechanisms that HCV uses to replicate in liver cells is poorly understood. In this project we aim to better understand how the viral glycoproteins, E1 and E2, function in the initiation of infection. In particular, we will examine how these glycoproteins bind to liver cell receptors and then mediate virus-cell membrane fusion. These processes lead to the penetration of the HCV genetic material into the cell where it is replicated. These studies are essential for the discovery of new targets for antiviral agents and vaccines.

丙型肝炎病毒（HCV）感染全球约3%的人口，目前生活在澳大利亚的HCV感染者为150，000 - 200，000人。慢性HCV感染与复发性、进行性恶化的肝病、肝硬化和肝细胞癌相关。目前的治疗（干扰素-利巴韦林）仅对40%的患者有效，并且通常伴有严重的副作用。HCV用于在肝细胞中复制的机制知之甚少。在这个项目中，我们的目标是更好地了解病毒糖蛋白，E1和E2，如何在感染的启动功能。特别是，我们将研究这些糖蛋白如何结合肝细胞受体，然后介导病毒细胞膜融合。这些过程导致HCV遗传物质渗透到细胞中，并在细胞中复制。这些研究对于发现抗病毒药物和疫苗的新靶点至关重要。